MedTrace Logo

A Study to Assess the Effects of Dexpramipexole in Participants With Eosinophilic COPD

NCT06533553 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-05-14

No results posted yet for this study

Summary

This is an open-label Phase II study assessing the PD of dexpramipexole 150 mg twice daily (BID) in participants with eosinophilic COPD. This study will help characterize the profile and duration of reductions of blood absolute eosinophil counts (AEC).

Conditions

Interventions

DRUG

Dexpramipexole Dihydrochloride

Administration of dexpramipexole tablet

Sponsors & Collaborators

  • Areteia Therapeutics

    lead INDUSTRY

Principal Investigators

  • Gerard J Criner, MD · Temple University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-09
Primary Completion
2025-10-31
Completion
2025-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06533553 on ClinicalTrials.gov